References
- Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report – 2011. J. Heart Lung Transplant. 30(10), 1078–1094 (2011).
- Mitchell RN. Graft vascular disease: immune response meets the vessel wall. Annu. Rev. Pathol. 4, 19–47 (2009).
- Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 117(16), 2131–2141 (2008).
- Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ. Res. 99(8), 801–815 (2006).
- Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 93(1), 1–10 (2012).
- Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(10), 1412–1418 (2009).
- Swirski FK, Libby P, Aikawa E et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117(1), 195–205 (2007).
- Tacke F, Alvarez D, Kaplan TJ et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117(1), 185–194 (2007).
- Swirski FK, Wildgruber M, Ueno T et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J. Clin. Invest. 120(7), 2627–2634 (2010).
- Schiopu A, Nadig SN, Cotoi OS, Hester J, van Rooijen N, Wood KJ. Inflammatory Ly-6C(hi) monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients. Atherosclerosis 223(2), 291–298 (2012).
- Yin R, Zhu J, Shao H et al. Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. J. Heart Lung Transplant. 26(5), 485–493 (2007).
- Raichlin E, Kushwaha SS. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr. Opin. Organ Transplant. 13(5), 543–550 (2008).
- Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J. Cardiovasc. Pharmacol. 46(4), 481–486 (2005).
- Nadig SN, Wieckiewicz J, Wu DC et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 16(7), 809–813 (2010).
- Feng G, Nadig SN, Bäckdahl L et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci. Transl. Med. 3(83), 83ra40 (2011).
- Hester J, Schiopu A, Nadig SN, Wood KJ. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am. J. Transplant. 12(8), 2008–2016 (2012).
- Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12(6), 417–430 (2012).
- Kao J, Kobashigawa J, Fishbein MC et al. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107(15), 1958–1961 (2003).
- Leuschner F, Dutta P, Gorbatov R et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29(11), 1005–1010 (2011).
- Saiura A, Sata M, Hiasa K et al. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler. Thromb. Vasc. Biol. 24(10), 1886–1890 (2004).